Biotech Values

[investorgold2002]

I wondered about the same. that they could get some contract manufacturing capabilities(unless this is difficult to get- which i doubt), some clinical trial and then get late stage marketing partner

the hardest part appears to me is characterization capabilities esp if it needs to be approved as substitutable.

Let's see what magic wheeler has in his bag for shareholders. I believe his strategy is for MNTA to stick with and grow it's Core business of characterization...So he probably doesn't want to do anything (even outsourced management) with manufacturing, conducting clinical trial, or marketing